Overview

Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
In vitro and in vivo data show promising results of adjunctive use of Chloroquine to standard tuberculosis therapy as Chloroquine enhances animicrobial effectiveness against intracellular MTB. To date, no safety data of the concurrent use of both treatments is availble. In a phase I trial, the investigators aim to evaluate safety and tolerability of the concurrent use of Chloroquine and standard anti-TB drug in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
University of Zurich
Treatments:
Chloroquine
Ethambutol
Isoniazid